{"prompt": "['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Weight', '4. Body weight 45 kg', 'Sex', '5. Male or female', 'a.', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'b. Female participants:', 'A female participant is eligible to participate if she is not pregnant (see Section 12.5;', 'Appendix 5), not breastfeeding, and at least one of the following conditions applies:', '(i)', 'Not a woman of childbearing potential (WOCBP) as defined in Section 12.5', '(Appendix 5)', 'OR', '(ii)', 'A WOCBP who agrees to follow the contraceptive guidance in Section 12.5', '(Appendix 5) during the treatment period and for at least 60 hours after the', 'last dose of study treatment.', 'Informed Consent', '6.', 'Capable of giving signed informed consent as described in Section 12.3 (Appendix', '3) which includes compliance with the requirements and restrictions listed in the', 'informed consent form (ICF) and in this protocol.', '6.2.', 'Exclusion Criteria', 'Participants are excluded from the study if any of the following criteria apply:', 'Medical Conditions', '1. Diagnosis of other clinically relevant lung disease (other than COPD), e.g.', 'sarcoidosis, tuberculosis, pulmonary fibrosis, severe bronchiectasis or lung cancer', '2. COPD due to alpha-l-antitrypsin deficiency', '3. Pulse oximetry < 88% at rest at screening. Participants should be tested while', 'breathing room air. However, participants living at high altitudes (above 5000 ft or', '1500 m above sea level) who are receiving supplemental oxygen can be included', 'provided they are receiving the equivalent of < 4L/min and screening oximetry is', 'measured while on their usual settings.', '4. Less than 14 days have elapsed from completion of a course of antibiotics or oral', 'corticosteroids for a recent COPD exacerbation', '23']['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '5. Participants with a peripheral blood neutrophil count < 1 X 109/L', '6. Diagnosis of pneumonia (chest X-ray or CT confirmed) within the 3 months prior to', 'screening', '7. Chest X-ray (posterior with lateral) or CT scan reveals evidence of a clinically', 'significant abnormality not believed to be due to the presence of COPD (historic data', 'up to 1 year may be used).', '8. History or current evidence of clinically significant renal disease, diabetes', 'mellitus/metabolic syndrome, hypertension, or any other clinically significant', 'cardiovascular, neurological, immunological, endocrine, or haematological', 'abnormality that is uncontrolled on permitted therapies. Significant is defined as any', 'disease that, in the opinion of the Investigator, would put the safety of the participants', 'at risk through study participation, or which would affect the safety analysis or other', 'analysis if the disease/condition exacerbated during the study.', '9. History of sensitivity to any of the study medications, or components thereof or a', 'history of drug or other allergy that, in the opinion of the investigator of GSK medical', 'monitor, contraindicates their participation.', '10. Current of chronic history of liver disease, or know hepatic or biliary abnormalities', \"(with the exception of Gilbert's syndrome or asymptomatic gallstones).\", '11. Abnormal and clinically significant 12-lead ECG finding. The investigator will', 'determine the clinical significance of each abnormal ECG finding in relation to the', \"subject's medical history and exclude participants who would be at undue risk by\", 'participating in the trial. An abnormal and clinically significant finding that would', 'preclude a subject from entering the trial is defined as a 12-lead tracing that is', 'interpreted as, but not limited to, any of the following:', '- AF with rapid ventricular rate > 120 bpm;', '- sustained or non-sustained VT', '-', 'second degree heat block Mobitz type II and third degree heart block (unless', 'pacemaker or defibrillator has been implanted)', '- QTcF 500 msec in patients with QRS < 120 msec and QTcF 530 msec in', 'patients with QRS 120 msec', '12. Previous lung surgery (e.g. lobectomy, pneumonectomy) or lung volume reduction', 'procedure.', 'Prior/Concomitant Therapy', '13. Current or expected chronic use of macrolide antibiotics during the study period for', 'the prevention of COPD exacerbations. Examples of chronic use include, but are not', 'limited to, daily or two to three times per week use for at least 3 months.', '14. Oral or injectable CYP3A4 or BRCP (breast cancer resistance protein) substrates with', 'a narrow therapeutic index (CYP3A4 substrates include, but are not limited to,', 'alfenatil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide,', 'quinidine, sirolimus, tacrolimus, and theophylline; BCRP substrates include, but are', '24']\n\n###\n\n", "completion": "END"}